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Abstract 
Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease (MJD), is 
an autosomal-dominant neurodegenerative disorder caused by a polyglutamine 
expansion in ataxin-3 (SCA3, MJD1) protein.  In biochemical experiments we demonstrate 
that mutant SCA3exp specifically associated with the type 1 inositol 1,4,5-trisphosphate 
receptor (InsP3R1), an intracellular calcium (Ca2+) release channel. In electrophysiological 
and Ca2+ imaging experiments we show that InsP3R1 are sensitized to activation by InsP3 
in the presence of mutant SCA3exp.  We found that feeding SCA3-YAC-84Q transgenic 
mice with dantrolene, a clinically relevant stabilizer of intracellular Ca2+ signaling, 
improved their motor performance and prevented neuronal cells loss in pontine nuclei 
and substantia nigra regions.  Our results indicate that deranged Ca2+ signaling may play 
an important role in SCA3 pathology and that Ca2+ signaling stabilizers such as 
dantrolene may be considered as potential therapeutic drugs for treatment of SCA3 
patients. 
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Introduction 
 Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease (MJD), is an 
autosomal-dominant neurodegenerative disorder that belongs to a group of polyglutamine 
(polyQ)-expansion diseases 1-3. The symptoms of SCA3 include gait ataxia, dysarthria, 
dysmetria, hyperreflexia, dystonia and ophthalmoplegia 4. The brain regions most affected in 
SCA3/MJD are dentate and pontine nuclei,  internal portion of globus pallidus,   sub-thalamic 
nucleus, substantia nigra,  and spinocerebellar tracts 5.  At molecular level the cause of SCA3 is 
a polyQ expansion in the carboxy-terminal of ataxin-3 (SCA3, MJD1) protein 6,7.  The ataxin-3 is 
a 43 kDa cytosolic protein that contains amino-terminal Josephin domain and 2 ubiquitin-
interactions motifs  8,9.  PolyQ-expansion occurs in carboxy-terminal region of ataxin-3 that does 
not contain any known functional motifs.  Despite intense efforts, the cellular pathogenic 
mechanism of SCA3 remains unclear.    
 Huntington’s disease is another member of polyQ-expansion disease family, which is 
caused by a polyQ-expansion in the context of Huntingtin protein (Htt).  In our previous studies 
we demonstrated that mutant Httexp protein specifically binds to and activates type 1 inositol 
1,4,5-trisphosphate receptor (InsP3R1) 10.  From these results we proposed that deranged Ca2+ 
signaling may play an important role in HD pathogenesis 11.  These ideas were supported by our 
studies with primary neuronal cultures from YAC128 HD mouse model 12,13.  It is generally 
assumed that many polyQ-expansion disorders share a common pathogenic mechanism 1-3.   
Here we set out to investigate if abnormal Ca2+ signaling also plays a role in SCA3 pathogenesis.  
In a series of biochemcial and functional experiments we investigated interactions between ataxin-
3 and InsP3R1.  We extended these findings to analysis of SCA3-YAC-84Q mouse model.  
Obtained results suggested that deranged neuronal Ca2+ signaling plays a significant role in SCA3 
pathology.  
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Results 
Mutant ataxin-3 specifically binds to and activates InsP3R1 in vitro 
   To determine if SCA3exp behaves similar to Httexp and also binds to the InsP3R1 carboxy-
terminal region, we expressed EGFP-SCA3-19Q, EGFP-SCA3-77Q and EGFP-SCA3-127Q 
proteins 14 in HEK293 cells and performed a series of GST pull-down experiments with 
bacterially-expressed InsP3R1 carboxy-terminal fragment GST-IC10 (aa F2627 - A2749 of rat 
InsP3R1).   The precipitated samples were analyzed by Western blotting with anti-GFP 
monoclonal antibodies.  We found that GST-IC10, but not GST, specifically associated with 
GFP-SCA3-77Q and GFP-SCA3-127Q proteins (Fig 1A).  Similar to Htt 10, association of ataxin-
3 with IC10 fragment was dependent on polyQ expansion as wild type EGFP-SCA3-19Q protein 
did not bind to GST-IC10 (Fig 1A).  In the next series of experiments we tested the association 
of full-length InsP3R1 with ataxin-3.  In these experiments we expressed full-length rat InsP3R1 
(RT1) in Sf9 cells by baculoviral infection and solubilized recombinant InsP3R1 (RT1) in 1% 
CHAPS.  The EGFP-SCA3-19Q, EGFP-SCA3-77Q and EGFP-SCA3-127Q proteins were 
transiently expressed in HEK293 cells as described above and solubilized in 1% CHAPS.  The  
mixture of RT1 and ataxin-3 containing lysates was precipitated with anti-InsP3R1 rabbit 
polyclonal antibodies (T443) 15 and analyzed by Western blotting with anti-GFP monoclonal 
antibodies.  Preimmune sera (P/S) were used in control immunoprecipitation experiments.  We 
found that full-length InsP3R1 associated with EGFP-SCA3-77Q and EGFP-SCA3-127Q mutant 
proteins, but not with the wild type EGFP-SCA3-19Q protein (Fig 1B).  Thus, association of full-
length InsP3R1 with ataxin-3 also depends on polyQ-expansion in ataxin-3 sequence.  
 To test functional effect of SCA3exp on InsP3R1, we expressed full-length InsP3R1 (RT1) in 
Sf9 cells by baculoviral infection, reconstituted recombinant InsP3R1 in planar lipid bilayers and 
induced channel activity by addition of 100 nM InsP3 to the cis chamber (Fig 1C).  The SCA3-
19Q and SCA3-77Q full-length proteins were expressed in bacteria as MBP (maltose-binding 
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protein) fusion proteins and purified by affinity chromatography followed by gel filtration.  
Obtained proteins were pure when analyzed by SDS-PAGE electrophoresis and Coomassie 
staining (data not shown).   Addition of purified MBP or MBP-SCA3-19Q proteins had no effect 
on channel activity of InsP3R1 in bilayers (Figs 1C, 1D).   In contrast, addition of MBP-SCA3-
77Q protein induced pronounced activation of InsP3R1 (Fig 1E, 1F).  In further experiments we 
generated baculoviruses encoding full-length SCA3-19Q and SCA3-77Q proteins.   Microsomes 
prepared from Sf9 cells coinfected with RT1 and SCA3-19Q or SCA3-77Q baculoviruses were 
fused to planar lipid bilayers.  In these experiments we found that InsP3R1 co-expressed with 
SCA3-77Q are much more sensitive to activation by InsP3 than the InsP3R1 co-expressed with 
SCA3-19Q (Supplementary Fig 1).  From these experiments we concluded that association of 
SCA3exp with InsP3R1 increases apparent affinity of InsP3R1 to activation by InsP3, similar to our 
previous findings with Httexp  10. 
Mutant ataxin-3 facilitates InsP3-induced Ca2+ release in cells 
 To determine the functional effects of SCA3exp on InsP3R1 in cells, we transfected cultured 
rat striatal medium spiny neurons (MSN) with SCA3-19Q, SCA3-77Q and SCA3-127Q 
expression plasmids.    To identify transfected cells, the SCA3 plasmids were cotransfected with 
enhanced green fluorescent protein (EGFP)-expressing plasmid. To stimulate InsP3R1-
mediated Ca2+ release, we challenged Fura-2-loaded MSNs with 10 μM 3, 5-
dihydroxyphenylglycine (DHPG), a specific mGluR1/5 receptor agonist. The local Ca2+ 
concentration in these experiments is estimated from the ratio of Fura-2 signals at 340 nm and 
380 nm excitation wavelengths as shown by pseudocolor images (Fig. 2A). The transfected 
cells were identified by GFP imaging (Fig. 2A, first column) prior to collecting Ca2+ imaging data.  
 Ten micromolar DHPG corresponds to a threshold concentration for mGluR1/5 receptor 
activation in MSNs, and only a small response to DHPG application at this concentration was 
observed in control MSNs transfected with EGFP plasmid alone (Fig 2A, first row, Figs 2B and 
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2C) and in MSNs transfected with SCA3-19Q plasmid (Fig 2A, second row, Figs 2D and 2E).  In 
contrast, significant response to 10 μM DHPG was observed in MSNs transfected with SCA3-
77Q plasmid (Fig 2A, third row, Figs 2F and 2G).  Even stronger response to DHPG was 
observed in MSNs transfected with SCA3-127Q plasmid (Fig 2A, fourth row, Figs 2H and 2I).   
On average, after the addition of 10 μM DHPG,  the peak 340/380 ratios were significantly 
(p<0.01) higher than basal 340/380 ratios in SCA3-77Q and SCA3-127Q transfected neurons, 
but not in SCA3-19Q and EGFP-only transfected neurons (Fig 2K).  Thus, we concluded that 
overexpression of SCA3exp mutant protein, but not of SCA3 wild type protein, sensitizes InsP3-
sensitive Ca2+ stores in cultured MSN. 
 To further investigate functional effects of SCA3exp on Ca2+ signaling in cells and to establish 
the relevance of our results for human disease, we performed a series of Fura-2 Ca2+ imaging 
experiments with primary human fibroblasts from from a healthy individual (hF) and a 
symptomatic SCA3 patient with 74Q expansion in ataxin-3 gene (hF-SCA3).  We discovered 
that application of 300 nM bradykinin (BK), an agonist of InsP3-coupled receptor,  induced much 
larger Ca2+ responses in hF-SCA3 cells than in control hF cells (Supplementary Fig 2).  From 
these experiments, we concluded that expression of mutant ataxin-3 proteins has potentiating 
effect on InsP3R-mediated Ca2+ release in SCA3 patient fibroblasts, consistent with our analysis 
of Ca2+ signals in cultured rat MSN transfected with mutant SCA3exp (Fig 2). 
Mutant ataxin-3 associates with InsP3R1 in vivo  
 To establish a relevance of our findings for SCA3 pathogenesis in vivo, we focused on 
analysis of SCA3-YAC-84Q mouse model 16.  The SCA3-YAC-84Q mice used in these studies 
have been re-created by in vitro fertilization from a frozen sperm (see Methods for details).  In 
the first series of experiments we assessed distribution of ataxin-3 protein in two brains from 12-
month-old SCA3-YAC-84Q mice and two brains from 14-month-old SCA3-YAC-15Q mice 16.   
We observed that the pattern of SCA3-84Q transgene expression and nuclear accumulation in 
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the aging SCA3-YAC-84Q mouse brains  corresponded closely with the regions most severely 
affected in SCA3 patients, with abundant nuclear accumulation of ataxin-3 in pontine nuclei (Pn), 
substantia nigra (SN) and dentate nuclei (Lat) regions (Supplementary Fig 3).  In contrast,  
nuclear accumulation of ataxin-3 was not detected in striatum (CPu), cortex and hippocampus 
(Supplementary Fig 3, data not shown), which are the brain regions relatively spared in 
MJD/SCA3 patients 5.  In SCA3-YAC-15Q mice ataxin-3 protein was expressed in a similar 
pattern but remained predominantly cytosolic and did not accumulate in the nucleus 
(Supplementary Fig 3). 
 To determine whether SCA3exp forms complex with InsP3R1 in vivo, we performed a series 
of immunoprecipitation experiments with cortical lysates from wild type and SCA3-YAC-84Q 
mouse brains.  Recombinant SCA3-19Q and SCA3-77Q proteins expressed in Sf9 cells were 
used as reference standards in these experiments (Fig 3).  We found that anti-InsP3R1 pAb 
(T443) precipitated SCA3-84Q from SCA3-YAC-84Q cortical lysates (Fig. 3, grey arrows).  
Consistent with in vitro binding experiments (Fig 1B), the association with InsP3R1 was specific 
for mutant SCA3exp, as endogenous mouse ataxin-3 was not precipitated by T443 pAb from wild 
type and SCA3-YAC-84Q mouse brains (Fig. 3, white arrows).  
Dantrolene alleviates motor coordination deficits in SCA3-YAC-84Q mice  
 Biochemical and functional interactions between SCA3exp and InsP3R1 (Figs 1-3, 
Supplementary Figs 1 and 2) suggested that deranged neuronal Ca2+ signaling may play a 
significant role in SCA3 pathogenesis.  To test this hypothesis, we initiated a dantrolene trial in 
SCA3-YAC-84Q mice.   Dantrolene is a skeletal muscle relaxant widely used in the clinic to treat 
malignant hyperthermia (MH) and muscle spasticity 17.  When used to treat MH, dantrolene acts 
by inhibiting excessive Ca2+ release from sarcoplasmic reticulum in skeletal muscles. In 
neuronal cells dantrolene has similar inhibitory effects on Ca2+ release from the endoplasmic 
reticulum 18.  The molecular target of dantrolene in muscle and neuronal cells is type 1 
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ryanodine receptor (RyanR1), an intracellular Ca2+ release channel.  In experiments  with 
cultured neuronal cells, dantrolene has been shown to have neuroprotective effect by inhibiting 
both cytosolic Ca2+ increase and neurotoxicity evoked by NMDA, glutamate, or potassium 
depolarization 18-22.   These results lead us to evaluate potential beneficial effects of dantrolene 
in SCA3-YAC-84Q mouse model. 
 In our studies 100 μg of dantrolene was resuspended in PBS and orally delivered to wild 
type (WT) and SCA3-YAC-84Q (SCA3) mice twice a week (Table 1, groups 2 and 4).   Control 
groups of WT and SCA3 mice were fed with PBS alone at the same time (Table 1, groups 1 and 
3).   The effectiveness of drug delivery was determined by 2 months of “drug dosage” trial. We 
found that 30 min after feeding dantrolene concentration in blood plasma was 1081.25 ± 261.91 
ng/ml and in brain it was 23.2 ± 4.2 ng/g (67 nM). Thus, we concluded that dantrolene accessed 
to the systemic circulation effectively from the gastrointestinal system, but penetrated blood 
brain barrier poorly, which is in agreement with the previous findings in the animal model of 
cerebral ischemia in gerbils 20.  
 The behavioral assessment of all 4 groups of mice was performed by using “beam walk” 
assay (see Methods for details). As in our previous studies 23, three kinds of beams (17 mm 
round, 11 mm round and 5 mm square) were used for testing. The “latency” and “number of 
footslips” were determined on each beam . When results were analyzed we found that control 
group of SCA3 mice (fed with PBS) exhibited a progressive impairment in beam-walking ability 
(longer beam traverse latencies and increased number of foot slips) with age and beam difficulty 
compared with control group of WT mice. The significant differences (p < 0.05) between beam 
performance of control SCA3 and control WT groups were observed at 10, 12 and 13.5 months 
of age on 17 mm round beam (Figs 4A, 4B); at 7.5, 10, 12 and 13.5 months of age on 11 mm 
round beam and 5 mm square beam (Figs. 4C, 4D, 4E, 4F).  Feeding dantrolene to WT mice 
had no significant effect on balance beam performance of these mice (Fig. 4A-4F).  However, 
feeding dantrolene to SCA3 mice improved their beam-walking performance, significantly 
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(p<0.05) shortening the latencies and decreasing the foot-slip numbers (Figs. 4A-4F). 
Significant differences (p < 0.05) of latency between SCA3 control group and dantrolene-fed 
SCA3 group were detected at 12 and 13.5 months of age on 17 round beam (Fig 4A); at 10, 12 
and 13.5 months of age on 11 mm round beam and 5 mm square beam (Fig 4C, 4E).  At 7.5, 10 
and 12 month points, the number of foot slips of dantrolene-fed SCA3 mice on all 3 beams were 
almost identical to control WT mice (Figs 4B, 4D, 4F). We noticed that following dantrolene 
withdrawal, the perfomance of both WT and SCA3 groups of mice was impaired, with increased 
latencies and elevated numbers of footslips (Figs 4A-4F).  This phenomenon is most likely to be 
due to removal of the sedative effect of dantrolene, which resulted in anxiousness of the mice. 
In spite of this “withdrawal effect” dantrolene-fed SCA3 mice still performed better than control 
SCA3 mice in most tasks at 13.5 months time point (Figs 4A-4F).  
 While conducting beam-walking assays, we observed that some aging mice exhibited 
periods of "crawling behavior" (defined as prolonged contact between the thorax and abdomen 
of the mice and beam surface, with the mice using forelimbs to drag themselves along the 
beam).  Two mice in SCA3 control group crawled on 11 mm round and 5 mm square beams at 
10 months time point, three mice in SCA3 control group crawled on 11 mm round beam and 5 
mm square beam at 12 and 13.5 months of age, and two mice in SCA3 dantrolene-fed group 
crawled on 5 mm square beam at 12 and 13.5 months of age. Furthermore, one mouse in SCA3 
control group fell off 5 mm square beam when tested at 12 and 13.5 months time points (Figs 
4E, 4F).  In contrast, none of the mice in WT groups exhibited crawling behavior or fell off the 
beams at any age tested. The incidence of crawling behavior was consistent with a general 
performance of these mice in balance beam assay, with SCA3 control group performing the 
worst, dantrolene-fed SCA3 group performing better and all the wild type mice traversing the 
beams without crawling. 
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 At the conclusion of beam walking behavioral experiments (13.5 months of age), we 
assessed gait abnormalities in the four groups of mice by using footprint pattern analysis (Fig. 
4G).  The footprint patterns were assessed quantitatively by the measurements of stride length 
and front/hind footprint overlap as we previously described 23 . We found that the stride length of 
SCA3 control mice was very significantly (p<0.001) shorter than WT control littermates (Figs. 4G, 
4H).  Dantrolene feeding significantly (p<0.01) increased the stride length of SCA3 mice, but 
had no obvious effects on stride length of WT mice (Figs. 4G, 4H).   We further found that 
front/hind footprint overlap was significantly higher in SCA3 control group than in WT control 
group (Fig 4I).  In contrast to stride length measure, footprint overlap deficit was not rescued by 
feeding dantrolene to SCA3 mice (Fig 4I).  
 
Dantrolene protects against neuronal loss in SCA3-YAC-84Q mice 
 To further evaluate potential neuroprotective effects of dantrolene, at the conclusion of 
behavioral analysis (13.5 months time point) the brains from all four groups of experimental mice 
were removed from skull and weighed after transcardial perfusion.  We found that the brains of 
control SCA3 mice (fed with PBS) weighted significantly less (p < 0.01) than the brains of 
control WT mice group (Fig 5A, Table 1). Feeding dantrolene to WT mice had no significant 
effect on brain weight of these mice (Fig 5A, Table 1), while the brain weight of SCA3 mice fed 
with dantrolene was higher than the brain weight of control SCA3 mice (Fig 5A, Table 1), 
although the difference did not reach a level of statistical significance.  
 In order to obtain quantitative information about neuronal loss in the experimental mice, we 
performed stereological analysis of these brains.   Our analysis was focused on pontine nuclei 
(Pn) and substantia nigra (SN) regions,  both of which severely affected in SCA3 patients 5.   
Our own experiements confirmed abundant accumulation of SCA3-84Q transgene in neurons 
from Pn and SN regions in brains form aging SCA3-YAC-84Q mice (SupFig 3).   For 
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stereological analysis NeuN-positive neurons in Pn and TH-positive neurons in SN were 
counted blindly with respect to the nature of slices (genotype and drug treatment).   We focused 
on TH-positive neurons in SN as dopaminergic neurons are most severely affected in SCA3 
patients  5 and our own analysis demonstrated that SCA3-84Q transgene is primarily expressed 
in SN dopaminergic neurons of SCA3-YAC-84Q mice (data not shown).   By stereological 
analysis we determined that control SCA3 mice (fed with PBS) showed significant neuronal loss 
in Pn (p < 0.05) and SN (p < 0.01) when compared with control WT mice (Figs. 5B and 5C, 
Table 1).  We further found that feeding of dantrolene had no significant effect on Pn and SN 
neuronal counts in WT mice but significantly increased Pn and SN neuronal counts (p < 0.01) in 
SCA3  mice (Figs. 5B and 5C, Table 1).  Our results indicated that feeding with dantrolene 
protected most Pn and SN neurons from cell death in brains of aging SCA3 mice (Figs. 5B and 
5C, Table 1).  
 
Discussion 
The  causes of neurodegeneration in SCA3 and other polyQ-expansion disorders are poorly 
understood.   Similar to other polyQ-expansion disorders, mutant ataxin-3 forms nuclear 
agreggates, and formation of these aggregates have been proposed to be toxic to the affected 
neurons 24,25.   The nuclear toxicity of ataxin-3 has been supported by recent genetic 
experiments with transgenic mouse model of SCA3 26.  Consistent with the presence of 
Josephin domain and ubiquitin-interactions motifs, ataxin-3 binds polyubiquitylated proteins and 
displays deubiquitylating activity in vitro 27,28.  In agreement with defects in ubiqutin-proteasomal 
pathway,    impaired proteasomal function has been implicated in SCA3 pathogenesis 29.  
Results of our studies indicate that in addition to forming “toxic aggregates” and causing 
“proteasomal deficiency”  mutant ataxin-3 is also able to destabilize neuronal Ca2+ signaling.  
We found that mutant ataxin-3 directly binds to the InsP3R1 (Figs 1A, 1B, 3) and increases 
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sensitivity of InsP3R1 to activation by InsP3 in functional assays (Figs 1C-1F, 2 and 
Supplementary Figs 1 and 2).   The mechanism of SCA3exp effects on InsP3R1 and Ca2+ 
signaling in our experiments are identical to actions of Httexp which we described previously 10.  
Studies of Httexp and Ca2+ signaling led us to propose “Ca2+ hypothesis of HD 11, and idea 
supported by our studies with primary neuronal cultures from YAC128 HD mouse model 12,13.  
Biochemical and functional interactions between mutant ataxin-3 and InsP3R1 (Figs 1 – 3, 
Supplementary Figs 1 and 2) suggested that deranged neuronal Ca2+ signaling may also play a 
significant role in SCA3 pathogenesis.  To test this hypothesis we evaluated the effects of 
dantrolene, a clinically relevant stabilizer of intracellular Ca2+ signaling and inhibitor of ryanodine 
receptor, on the phenotype of SCA3-YAC-84Q transgenic mouse.  We found that feeding 
SCA3-YAC-84Q mice with dantrolene improved their motor performance  (Fig 4) and prevented 
neuronal cells loss in pontine nuclei and substantia nigra regions (Fig 5 and Table 1).  Our 
results indicate that deranged neuronal Ca2+ signaling may play an important role in SCA3 
pathology and that Ca2+ signaling stabilizers such as dantrolene may be considered as potential 
therapeutic drugs for treatment of SCA3 patients. 
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MATERIALS and METHODS 
SCA3 mouse colonies.  Generation of    SCA3-YAC-15Q and SCA3-YAC-84Q mice have been 
previously described 16.  For our studies SCA3-YAC-84Q mouse was recreated by IVF using 
C57BL/6 mouse strain egg and SCA3-YAC-84Q mouse frozen sperm.  
In vitro binding experiments  
 EGFP-SCA3-19Q, EGFP-SCA3-77Q and EGFP-SCA3-127Q expression plasmids have 
been previously described 14.  GST-IC10 expression plasmid (aa F2627 - A2749 of rat InsP3R1) 
has been previously described 10. GST and GST-IC10 proteins were expressed in the BL21 E. 
coli strain and purified on glutathione-agarose beads. EGFP-SCA3-19Q/77Q/127Q proteins 
were expressed in HEK293 cells by calcium-phosphate transfection.  48 hr after transfection, 
HEK293 cells were collected with ice-cold PBS and solubilized for 30 min at 4°C in extraction 
buffer A (1% CHAPS, 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4 [pH 7.2], 
5 mM EDTA, 5 mM EGTA, and protease inhibitors). Extracts were clarified by centrifugation for 
20 min at 100,000 × g and incubated for 1 hr at 4°C with GST or GST-IC10 proteins. Beads 
were washed three times with extraction buffer A. Attached proteins were analyzed by Western 
blotting with anti-GFP monoclonal antibodies. 
 Full-length rat InsP3R1 (RT1)-encoding baculoviruses were previously described 30. The 
EGFP-SCA3-19Q, EGFP-SCA3-77Q and EGFP-SCA3-127Q proteins were transiently 
expressed in HEK293 cells as described above and solubilized in 1% CHAPS.  The mixture of 
RT1 and ataxin-3 containing lysates was precipitated with anti-InsP3R1 polyclonal antibody 
(T443) 15 attached to protein A-Sepharose beads and analyzed by Western blotting with anti-
GFP monoclonal antibodies.  Preimmune sera (P/S) were used in control immunoprecipitation 
experiments. 
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Planar Lipid Bilayer Experiments. Single-channel recordings of recombinant InsP3R1 (RT1) 
were performed as previously described 10 at 0 mV transmembrane potential using 50 mM Ba2+ 
(trans) as a charge carrier. The cis (cytosolic) chamber contained 110 mM Tris dissolved in 
HEPES (pH 7.35), 0.5 mM Na2ATP, pCa 6.7 (0.2 mM EGTA + 0.14 mM CaCl2) 31. InsP3R1 were 
activated by addition of 100 nM InsP3 (Alexis) to the cis chamber as indicated in the text.  
Coding sequences of SCA3-19Q/77Q proteins were subcloned into pMAL2 bacterial expression 
vector (New England Biolabs).  MBP, MBP-SCA3-19Q, MBP-SCA3-77Q proteins were 
expressed in BL21 E. coli, purified on amylose resin (New England Biolabs) followed by gel 
filtration on Sephadex-10 column (AKTA FPLC, Amersham-Pharmacia).  The proteins were 
dialyzed overnight against cis recording buffer (110 mM Tris/HEPES [pH 7.35]), and added in 1 
μl volume (0.3 mg/ml protein with addition of 0.02 mM ruthenium red) directly to the cis side of 
the bilayer containing InsP3R1 without stirring. Exposure of InsP3R1 to the test proteins was 
terminated 2–3 min after addition by stirring the cis chamber for 30 s (1:3000 dilution of test 
protein stocks). The InsP3R1 single-channel currents were amplified (Warner OC-725), filtered 
at 1 kHz by a low-pass eight-pole Bessel filter, digitized at 5 kHz (Digidata 1200, Axon 
Instruments), and stored on computer hard drive and recordable optical discs. For off-line 
computer analysis (pClamp 6, Axon Instruments), currents were filtered digitally at 500 Hz. For 
presentation of the current traces, data were filtered at 200 Hz. 
Ca2+ Imaging Experiments. The rat medium spiny neuronal (MSN) cultures on poly-D-lysine 
(Sigma) coated 12 mm round glass coverslips were established as previously described 10. The 
5 μM of cytosine arabinoside (AraC, Sigma) was added at 2–4 DIV to inhibit glial cell growth.  
SCA3-19Q, SCA3-77Q and SCA3-130Q expression plasmids in pcDNA3 vector were generated 
by subcloning from EGFP-SCA3 plasmids described above. At 20 DIV the MSN cultures were 
transfected by the calcium-phosphate method with EGFP-C3 plasmid (Clontech) or a 1:3 
mixture of EGFP: SCA3 expression plasmids as indicated in the text. 48 hr after transfection, 
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the MSN neurons were loaded with 5 μM Fura-2-AM (Molecular Probes) in artificial 
cerebrospinal fluid (ACSF) (140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM 
HEPES [pH 7.3]) for 45 min at 37°C. For imaging experiments the coverslips were mounted 
onto a recording/perfusion chamber (RC-26G, Warner Instrument) maintained at 37°C (PH1, 
Warner Instrument), positioned on the movable stage of an Olympus IX-70 inverted microscope, 
and perfused with ACSF media by gravity flow. Following GFP imaging, the coverslip was 
washed extensively with Ca2+-free ACSF (omitted CaCl2 from ACSF and supplemented with 100 
μM EGTA). In Ca2+ imaging experiments the MSN cells were intermittently excited by 340 nm 
and 380 nm UV light (DeltaRAM illuminator, PTI) using a Fura-2 dichroic filter cube (Chroma 
Technologies) and 60× UV-grade oil-immersed objective (Olympus). The emitted light was 
collected by an IC-300 camera (PTI), and the images were digitized by ImageMaster Pro 
software (PTI). Baseline (6 min) measurements were obtained prior to bath application of 10 μM 
3, 5-DHPG (Tocris) dissolved in Ca2+-free ACSF. The DHPG solutions were prewarmed to 37°C 
before application to MSNs. Images at 340 and 380 nm excitation wavelengths were captured 
every 5 s and shown as 340/380 image ratios at time points as indicated. Background 
fluorescence was determined according to manufacturer's (PTI) recommendations and 
subtracted. 
Brain immunoprecipitations. Brains of wild type and SCA3-YAC-84Q mice were collected out 
of skull. After taking away cerebella, the brain samples were homogenized and solubilized at 
4ºC for 2 hr in extraction buffer A (1% CHAPS, 137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4, 
1.4mM KH2PO4 [pH7.2], 5mM EDTA, 5mM EGTA and protease inhibitors). The homogenates 
were cleared by 30 min centrifugation at 50,000 rpm in TL-100 and incubated with anti-InsPR3 
polyclonal antibodies (T443) attached to protein-A Sepharose CL-4B beads (Amersham 
Biosciences) at 4ºC for 3 hr. The resulted beads were washed with extraction buffer A and  
analyzed by Western blotting with anti-Ataxin-3 monoclonal antibody (Chemicon, MAB5360). 
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Drug delivery in mice. Dantrolene was delivered to mice by an approach that we used 
previously in tetrabenzine trial in YAC128-HD mice 23.  Briefly,  groups of wild type and SCA3-
YAC-84Q mice were fed with 100 μg dantrolene suspended in 50 µl PBS with 2% corn flour 
resulting in the dosage 5 mg/kg.  The control groups were fed with 2% corn flour in PBS.  All 
mice were fed orally twice a week from 2 to 12 months old. In order to decide the concentration 
of dantrolene in mouse brains, 5 wild type mice of 2 months old were fed with dantrolene for 2 
months with the same dosage (5 mg/kg) and anesthetized 30 min after the last dantrolene 
feeding. The blood samples of 5 mice were harvested into a tube containing 50 µl ACD solution 
(2.2 g sodium citrate; 0.8 g citric acid, monohydrate; 2.24 g glucose, anhydrous dissolved in 
dH2O to the final volume 100ml). After spinning the blood samples at 4ºC, 10,000 rpm for 10 
min, plasma was isolated and transferred to -80 ºC immediately.  The brains were collected at 
the same time and snap frozen in liquid nitrogen. The plasma and brain samples from each 
mouse were numbered and shipped on dry ice to the core facility of the department of 
Biochemistry in UT Southwestern for analysis by HPLC. 
Motor coordination assessments in mice. The motor coordination experiments were 
performed as previously described 23. The "beam walking" assay was carried out using a home-
made experimental setup. The 17 mm round plastic beam, 11 mm round plastic beam, and 5 
mm square wood beam were used in our studies. At each time point, the mice were trained on 
beams for 3 consecutive days (4 trials /d) to traverse the beam to the enclosed box. Once the 
stable baseline of performance was obtained, the mice were tested in three consecutive trials on 
17 and 11 mm round plastic beams and 5 mm square wood beam, in each case progressing 
from the widest to the narrowest beam. The latency to traverse the middle 80 cm of each beam 
and the number of times the hind feet slipped off each beam were recorded for each trial. For 
each measure, the mean scores of the three trials for each beam were used in the analysis. 
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For the footprint test, the forepaws and hindpaws of the mice were coated with purple and green 
nontoxic paints, respectively. The mice were trained to walk along a 50-cm-long, 10-cm-wide, 
paper-covered runway (with 10-cm-high walls) into an enclosed box. All the mice were given 3 
runs/d for 3 consecutive days. A fresh sheet of white paper was placed on the floor of the 
runway for each run. The footprint patterns were assessed quantitatively by the measurements 
of stride length and front/hindpaw overlap as we described previously 23. 
Neuropathological assessments in mice. The neuropathological assessments were 
performed as previously described 23. After all the behavioral testings (13.5 months time point), 
the mice were terminally anesthetized by pentobarbital with the dosage of 60 mg/kg and 
perfused transcardially with 20 ml of 0.9% saline followed by 100 ml of fixative (4% 
paraformaldehyde in 0.1 M PBS, pH 7.4). All brains were removed from skull, weighed and 
transferred to postfixative (4% paraformaldehyde in 0.1 M PBS, pH 7.4). After postfixation 
overnight at 4°C, the brains were infiltrated in 20–30% (w/v) sucrose in PBS at 4°C for 24-48 hr 
until falling to the bottom. The brains were frozen on dry ice and cut to 30-µm-thick coronal 
sections using a Leica (Bannockburn, IL) SM2000R sliding microtome. The coronal slices 
spaced 90 µm apart throughout the pontine (Pn) were stained with anti-NeuN monoclonal 
antibody (1:1000 dilution; Millipore, Billerica, MA). The coronal sections spaced 120 µm apart 
throughout the substantia nigra (SN) were stained with anti- tyrosine hydroxylase (TH) 
monoclonal antibody (1:400 dilution; Millipore, Billerica, MA).  Biotinylated anti-mouse IgG 
reagent was used in all the staining as the secondary antibodies (1:250 dilution; Vector 
Laboratories, Burlington, Ontario, Canada) (M.O.M kit). Signal was amplified with an ABC Elite 
kit (Vector Laboratories) and detected with diaminobenzidine (Vector Laboratories). All 
quantitative stereological analyses were performed blindly with respect to the nature of slices 
(genotype and drug feeding) using Stereoinvestigator setup and software (MicroBrightField, 
Williston, VT). For neuronal counting in Pn, the grid size was set to 250 x 200 µm and the 
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counting frame size was 40 x 40 µm. For neuronal counting in SN, the grid size was set to 130 x 
100 µm and the counting frame size was 50 x 50 µm. The average slice thickness after 
histological processing was determined to be 22 µm. 
Statistical data analysis. For comparison between two groups, Student's unpaired t test was 
used to statistically analyze data.  
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Figure 1.  Biochemical and functional interactions between ataxin-3 and InsP3R1.  
(A) GST/GST-IC10 pull-down experiments of EGFP-SCA3-19Q/77Q/127Q proteins from 
HEK293 cell extracts. 
(B) Immunoprecipitation of EGFP-SCA3/19Q/77Q/127Q from HEK293 cell lysates with full-
length InsP3R1 (RT1) expressed in Sf9 cells. Anti-InsP3R1 polyclonal antibodies (T443) and 
corresponding control preimmune sera (P/S) were used for precipitation.   
The precipitated fractions on panels A and B were analyzed by Western blotting with anti-GFP 
monoclonal antibodies.  
(C, E) Effects of MBP, MBP-SCA3-19Q and MBP-SCA3-77Q on the activity of recombinant 
InsP3R1 in planar lipid bilayers at 100 nM InsP3. Each current trace corresponds to 10 s (2 s for 
expanded traces) of current recording for the same experiment.   
(D, F) The average open probability (Po) of InsP3R1 at 100 nM of InsP3 in the presence of MBP, 
MBP-SCA3-19Q and MBP-SCA3-77Q.  The average Po was calculated for a 5 s window of time 
and plotted for the duration of an experiment. The times of InsP3, MBP, MBP-SCA3-19Q and 
MBP-SCA3-77Q additions are shown above the Po plot.  Data from the same experiment are 
shown on (C, D) and (E, F). Similar results were obtained in at least three independent 
experiments with MBP-SCA3-19Q and MBP-SCA3-77Q. 
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Figure 2.  Effects of ataxin-3 on DHPG-induced Ca2+ release in MSN.  
(A) Representative images showing Fura-2 340/380 ratios in transfected rat MSNs. The 
pseudocolor calibration scale for 340/380 ratios is shown on the right. Ratio recordings are 
shown for 10 μM DHPG-induced Ca2+ transients in MSNs transfected with EGFP (first row), 
EGFP + SCA3-19Q (second row), EGFP + SCA3-77Q (third row), and EGFP + SCA3-127Q 
(fourth row). The recordings were performed in Ca2+-free ACSF containing 100 μM EGTA. GFP 
images (1st column) were captured before Ca2+ imaging to identify transfected cells. 340/380 
ratio images are shown for MSN neurons 1 min before (2nd column), and 8 s, 30 s, 1 min, 2 min, 
and 3 min after application of 10 μM DHPG as indicated. We used SCA3: EGFP plasmids at a 
3:1 ratio during transfections, which probably resulted in the expression of SCA3 in some GFP-
negative MSNs.  The GFP-negative cells that respond to 10 μM DHPG in the third and fourth 
row (triangle arrow) are interpreted to be the neurons transfected with SCA3-77Q or SCA3-
127Q plasmid alone.  Only GFP-positive MSNs were considered for quantitative analyses.  
(B, D, F, H) Basal and peak 340/380 ratios are shown for individual MSN neurons transfected 
with EGFP (B), EGFP+SCA3-19Q (D), EGFP+SCA3-77Q (F), EGFP+SCA3-127Q (H). The 
experiments were performed as described on panel A.  The basal ratios were determined 1 min 
prior to DHPG application (−1 min). The peak ratios were measured from maximal signals 
observed within 30 s after DHPG application. 340/380 ratio traces for representative cells 
(marked *) are shown in (C), (E), (G) and (I).  Time of DHPG application is shown. Similar 
results were obtained in four independent transfections.  
(K) Summary of MSN Ca2+ imaging experiments with SCA3 constructs. Average basal and 
DHPG-evoked peak 340/380 ratios from four independent transfections are shown as mean ± 
SEM (n = number of cells).  The peak ratios in MSNs transfected with EGFP + SCA3-77Q and 
EGFP + SCA3-127Q are significantly (***p < 0.01, paired t test) higher than the basal ratios in 
the same cells. 
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Figure 3.  Association of ataxin-3 with InsP3R1 in vivo . 
Cortical lysates from WT and SCA3-YAC-84Q mouse were precipitated by anti-InsP3R1 pAb 
(T443) and analyzed by Western blotting with anti-ataxin-3 mAb.  Lysates from Sf9 cells 
infected with SCA3-19Q (white arrow) and SCA3-77Q (grey arrow) recombinant baculoviruses 
were used as reference standards.  Endogenous mouse ataxin-3 (white arrow) was detected by 
anti-ataxin3 (atx3) mAb in cortical lysates from the wild type and SCA3-YAC-84Q mice.  SCA3-
84Q transgene (grey arrow) were detected in cortical lysates from the SCA3-YAC-84Q mouse.  
Anti-InsP3R1 pAb (T443) precipitated SCA3-84Q (grey arrow), but not the endogenous ataxin-3.  
Preimmune serum (P/S) was used as a negative control for T443 immunoprecipitation 
experiments. 
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Figure 4.  Motor coordination  performance of  WT and SCA3 mice in dantrolene trial. 
(A-F)  Beam walk assay.  The average time to cross the beam (A, C, E) and the average 
number of foot slips on the beam (B, D, F) are shown for beam walking experiments performed 
with 17 mm round plastic beam (A, B), 11 mm round plastic beam (C, D), and 5 mm square 
wood beam (E, F). The data for WT control mice (open black circles), SCA3 control mice (filled 
black circles), WT mice fed with dantrolene  (open red circles), SCA3 mice fed with dantrolene 
(filled red circles) are shown as mean ± SEM (for the number of mice in each group, see Table 
1) at 2, 4, 7.5, 10, 12 and 13.5 month (washout) time points. While counting the footslips of the 
mice with “crawling behavior”, we considered every step as one footslip. *** p < 0.05, significant 
differences between control SCA3 group and dantrolene-fed SCA3 group.  “1F” on panels E and 
F  means one mouse failed the test. 
(G-I) Gait analysis.  (G) The footprint patterns of 13.5-month-old SCA3 and WT mice. The 
footprints for control and dantrolene groups are shown for both WT and SCA3 mice.  
(H) Stride lengths of WT and SCA3 ice in dantrolene trial are shown as mean ± SEM (for the 
number of mice in each group, see Table 1). Feeding dantrolene to SCA3 mice significantly 
(p<0.001) increased the stride lengths.  
(I) Front/hind footprint overlaps of WT and SCA3 mice in dantrolene trial are presented as mean 
± SEM.  Feeding dantrolene to SCA3 mice had no effect on front/hind paw overlaps.  
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Figure 5.  Neuroanatomical analysis of WT and SCA3 mice in dantrolene trial.  
(A) Average brain weight of 13.5-month-old WT and SCA3 mice. The brain weight of control 
SCA3 mice is significantly reduced compared with control WT group (p < 0.01). The brain 
weight of SCA3 mice fed with dantrolene is higher than control SCA3 mice, but the difference is 
not statistically significant.  
(B) Average pontine nuclei (Pn) neuronal counts of 13.5-month-old WT and SCA3 mice are 
shown as mean ± SEM (for the number of mice in each group, see Table 1) . Control SCA3 
mice showed significant Pn neuronal loss (***p < 0.05) compared with control WT mice. SCA3 
mice fed with dantrolene exhibited significantly (***p < 0.01) increased Pn neuronal counts 
compared with control SCA3 mice.  
(C) Average substantia nigra (SN) neuronal counts of TH-positive neurons from 13.5-month-old 
WT and SCA3 mice are shown as mean ± SEM (for the number of mice in each group, see 
Table 1).  The SN-TH neuronal number in control SCA3 mice is significantly lower (***p < 0.01) 
than in control WT mice. In SCA3 mice fed with dantrolene, the SN-TH neuronal counts are 
significantly (***p < 0.01) increased when compared to control SCA3 mice.  
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Table 1.  Dantrolne trial in SCA3-YAC-84Q mice. 
Four groups of mice were tested in our experiments. At 2 months of age, WT and 84Q mice were divided into two groups each and 
drug treatment was initiated. The group number, group name, number and genotype of mice in each group, and dose of single drug 
treatment (twice/week) are shown for each group. Also shown is the estimated drug dosage in mg/kg body weight.  The results of 
neuroanatomical analysis are shown for each group.  The average brain weight, Pn neuronal counts and SN-TH neuronal counts are 
shown as mean ± SEM (n = number of mice in each group). 
 
Group 
number Group name 
Number of 
female mice
Mouse 
genotype 
Single dose 
(2/wk) (50µl)
Drug dosage 
(mg/kg/3 days) 
Brain weight 
(g) Pn counts SN-TH counts
1 WT-Ctrl 10 WT 50 µl PBS PBS 0.500 ± 0.008 43368 ± 1811 11026 ± 284 
2 WT-Dan 7 WT 100 µg Dantrolene 
5 mg 
Dantrolene 0.501 ± 0.004 43659 ±2203 11202 ± 254 
3 SCA3-Ctrl 8 SCA3-YAC-84Q 50 µl PBS PBS 0.451 ± 0.007 37021 ± 1000 9384 ± 250 
4 SCA3-Dan 10 SCA3-YAC-84Q 
100 µg 
Dantrolene 
5 mg 
Dantrolene 0.470 ± 0.007 43642 ± 1725 10699 ± 239 
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